Fusokines involving cytokines with strongly reduced receptor binding affinities
First Claim
Patent Images
1. A composition comprising a fusion protein comprising at least two cytokines, wherein the cytokines are CC chemokine 20 (CCL20) and mutant human interleukin-1 beta (IL-1β
- ) and wherein IL-1β
comprises a mutation selected from R120G, Q131G, H146A, and Q148G that reduces binding activity of IL-1β
to its receptor as compared to wild type IL-1β
, and the CCL20 is wild-type and provides cell-specific targeting that restores activity of the mutant IL-1β
on the targeted cells.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
-
Citations
6 Claims
-
1. A composition comprising a fusion protein comprising at least two cytokines, wherein the cytokines are CC chemokine 20 (CCL20) and mutant human interleukin-1 beta (IL-1β
- ) and wherein IL-1β
comprises a mutation selected from R120G, Q131G, H146A, and Q148G that reduces binding activity of IL-1β
to its receptor as compared to wild type IL-1β
, and the CCL20 is wild-type and provides cell-specific targeting that restores activity of the mutant IL-1β
on the targeted cells. - View Dependent Claims (2, 3, 4, 5, 6)
- ) and wherein IL-1β
Specification